alexa Zeng Quan Yang | Wayne State University
ISSN: 2329-6577

Biological Systems: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
 
 

Zeng Quan Yang

Zeng Quan Yang Zeng Quan Yang
Karmanos Cancer Institute
Department of Oncology
Wayne State University
USA
Biography

Dr. Zeng Quan Yang is currently working as Assistant Professor in Karmanos Cancer Institute at Department of Oncology, Wayne State University, USA.

Research Interest

The primary focus of my research work is on the histone demethylase GASC1(Gene Amplified in Squamous Cell Carcinoma 1) in human cancers. I originally cloned the GASC1 gene when I was a PhD student at the Tokyo Medical and DentalUniversity in Japan. Shortly thereafter, as a postdoctoral fellow at the University of Michigan Cancer Center, I carried out research aimed at better understanding of the genetic basis and molecular mechanisms for the development and progression of human breast cancer. Now at the Karmanos Cancer Institute and WayneStateUniversity, I have extended my research to study the involvement of genetic and epigenetic alterations, specifically histone demethylase GASC1, in human breast, prostate and esophageal tumorigenesis. Using various cancer model cells, we demonstrated that over-production of GASC1 induces alterations in epigenetic histone methylation and affects the expression of key genes that are implicated in carcinogenesis and stem cell properties in human cancer. Furthermore, GASC1 represents highly promising anti-cancer therapeutic targets; a number of GASC1 inhibitors have been identified and reported. My lab, collaborated with others, are current test these GASC1 inhibitors in breast and prostate cancer in vitro and in vivo, and ultimately develop GASC1 inhibitors as new epi-drugs for the treatment of cancer.

Certificate
Certificate
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords